Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3
Nexalin Technology (Nasdaq: NXL) announces an upcoming investor webinar scheduled for April 3, 2025, at 4:15 p.m. ET. The event, hosted by RedChip Companies, will feature CEO Mark White presenting insights on the company's:
1. Non-invasive frequency-based deep brain stimulation device
2. Growing clinical data supporting their technology
3. Progress on the new Gen-3 HALO™ Clarity & Virtual Clinic model
The company's solutions have demonstrated clinically meaningful improvements in treating insomnia, PTSD, and traumatic brain injuries. These conditions, affecting millions with treatment options, position Nexalin in a market projected to reach $537 billion by 2030. The webinar will conclude with a live Q&A session.
Nexalin Technology (Nasdaq: NXL) annuncia un prossimo webinar per investitori programmato per il 3 aprile 2025, alle 16:15 ET. L'evento, ospitato da RedChip Companies, vedrà il CEO Mark White presentare approfondimenti sulla compagnia:
1. Dispositivo per la stimolazione profonda del cervello basato su frequenze non invasive
2. Crescente quantità di dati clinici a supporto della loro tecnologia
3. Progressi sul nuovo modello Gen-3 HALO™ Clarity & Virtual Clinic
Le soluzioni dell'azienda hanno dimostrato miglioramenti clinicamente significativi nel trattamento di insonnia, PTSD e lesioni cerebrali traumatiche. Queste condizioni, che colpiscono milioni di persone con opzioni di trattamento, posizionano Nexalin in un mercato che si prevede raggiunga 537 miliardi di dollari entro il 2030. Il webinar si concluderà con una sessione di domande e risposte dal vivo.
Nexalin Technology (Nasdaq: NXL) anuncia un próximo seminario web para inversores programado para el 3 de abril de 2025, a las 4:15 p.m. ET. El evento, organizado por RedChip Companies, contará con la presentación del CEO Mark White, quien ofrecerá información sobre la compañía:
1. Dispositivo de estimulación cerebral profunda basado en frecuencias no invasivas
2. Creciente cantidad de datos clínicos que respaldan su tecnología
3. Avances en el nuevo modelo Gen-3 HALO™ Clarity & Virtual Clinic
Las soluciones de la empresa han demostrado mejoras clínicamente significativas en el tratamiento de insomnio, PTSD y lesiones cerebrales traumáticas. Estas condiciones, que afectan a millones de personas con opciones de tratamiento, posicionan a Nexalin en un mercado que se proyecta alcanzará 537 mil millones de dólares para 2030. El seminario web concluirá con una sesión de preguntas y respuestas en vivo.
Nexalin Technology (Nasdaq: NXL)은 2025년 4월 3일 오후 4시 15분 ET로 예정된 투자자 웨비나를 발표합니다. RedChip Companies가 주최하는 이번 행사에서는 CEO Mark White가 회사에 대한 통찰력을 발표할 예정입니다:
1. 비침습적 주파수 기반 깊은 뇌 자극 장치
2. 그들의 기술을 지원하는 증가하는 임상 데이터
3. 새로운 Gen-3 HALO™ Clarity & Virtual Clinic 모델에 대한 진행 상황
회사의 솔루션은 불면증, PTSD 및 외상성 뇌 손상 치료에서 임상적으로 의미 있는 개선을 보여주었습니다. 이러한 상태는 치료 옵션이 있는 수백만 명에게 영향을 미치며, Nexalin을 2030년까지 5,370억 달러에 이를 것으로 예상되는 시장에 위치시킵니다. 웨비나는 라이브 Q&A 세션으로 마무리됩니다.
Nexalin Technology (Nasdaq: NXL) annonce un prochain webinaire pour investisseurs prévu pour le 3 avril 2025 à 16h15 ET. L'événement, organisé par RedChip Companies, présentera le PDG Mark White qui exposera des informations sur l'entreprise :
1. Dispositif de stimulation cérébrale profonde non invasive basé sur des fréquences
2. Données cliniques croissantes soutenant leur technologie
3. Progrès sur le nouveau modèle Gen-3 HALO™ Clarity & Virtual Clinic
Les solutions de l'entreprise ont démontré des améliorations cliniquement significatives dans le traitement de l'insomnie, du PTSD et des lésions cérébrales traumatiques. Ces conditions, touchant des millions de personnes avec des options de traitement, positionnent Nexalin sur un marché qui devrait atteindre 537 milliards de dollars d'ici 2030. Le webinaire se terminera par une session de questions-réponses en direct.
Nexalin Technology (Nasdaq: NXL) kündigt ein bevorstehendes Investoren-Webinar an, das für den 3. April 2025 um 16:15 Uhr ET geplant ist. Die Veranstaltung, die von RedChip Companies ausgerichtet wird, wird CEO Mark White präsentieren, der Einblicke in das Unternehmen geben wird:
1. Nicht-invasive, frequenzbasierte tiefe Hirnstimulationseinheit
2. Wachsende klinische Daten, die ihre Technologie unterstützen
3. Fortschritte beim neuen Gen-3 HALO™ Clarity & Virtual Clinic Modell
Die Lösungen des Unternehmens haben klinisch signifikante Verbesserungen bei der Behandlung von Schlaflosigkeit, PTSD und traumatischen Hirnverletzungen gezeigt. Diese Zustände, die Millionen von Menschen mit Behandlungsoptionen betreffen, positionieren Nexalin in einem Markt, der voraussichtlich bis 2030 537 Milliarden Dollar erreichen wird. Das Webinar endet mit einer Live-Q&A-Session.
- Company operates in a large market projected to reach $537 billion by 2030
- Clinical data shows meaningful improvements in treating multiple conditions
- Development of new Gen-3 HALO™ Clarity & Virtual Clinic model indicates product innovation
- None.
Houston, TX, March 26, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) is pleased to invite investors to a webinar on April 3, 2025, at 4:15 p.m. ET.
The exclusive event, hosted by RedChip Companies, will feature Nexalin CEO Mark White, who will share insight into the Company’s growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as progress on its new Gen-3 HALO™ Clarity & Virtual Clinic model. Nexalin’s solutions have shown clinically meaningful improvements in treating conditions such as insomnia, PTSD, and traumatic brain injuries—conditions that affect millions but have limited effective treatments—positioning Nexalin as an emerging leader in a market poised for substantial growth, projected to reach
To register for the free webinar, please visit: https://redchip.zoom.us/webinar/register/WN_IVzODZ1yS-Km1Xid5E2QyQ#/registration
Questions can be pre-submitted to NXL@redchip.com or online during the live event.
About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: https://nexalin.com/.
FORWARD-LOOKING STATEMENTS
This press release contains statements that constitute "forward-looking statements," These statements relate to future events or Nexalin’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or Nexalin’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2023 and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC's website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
NXL@redchip.com
FAQ
When is Nexalin Technology (NXL) hosting its investor webinar?
What medical conditions does Nexalin's (NXL) deep brain stimulation device treat?
What is the market size projection for Nexalin's (NXL) treatment solutions?
What will be discussed in Nexalin's (NXL) April 2025 investor webinar?
